company background image
CDXC

ChromaDex NasdaqCM:CDXC Stock Report

Last Price

US$1.69

Market Cap

US$115.8m

7D

-10.6%

1Y

-80.2%

Updated

14 Aug, 2022

Data

Company Financials +
CDXC fundamental analysis
Snowflake Score
Valuation4/6
Future Growth5/6
Past Performance0/6
Financial Health4/6
Dividends0/6

CDXC Stock Overview

ChromaDex Corporation operates as a bioscience company focusing on healthy aging.

ChromaDex Corporation Competitors

Price History & Performance

Summary of all time highs, changes and price drops for ChromaDex
Historical stock prices
Current Share PriceUS$1.69
52 Week HighUS$8.75
52 Week LowUS$1.51
Beta1.7
1 Month Change-5.59%
3 Month Change6.29%
1 Year Change-80.21%
3 Year Change-60.24%
5 Year Change-48.48%
Change since IPO-84.98%

Recent News & Updates

Aug 15

ChromaDex wins patent challenge as US regulator rejects Thorne Research's demand to invalidate patent

ChromaDex (NASDAQ:CDXC) said Thorne Research lost a patent challenge related to U.S. Patent No. 8,197,807 which is for compositions including nicotinamide riboside ChromaDex noted that it is the exclusive supplier of nicotinamide riboside chloride, Niagen — a supplement. The company said the U.S. Patent & Trademark Office's Patent Trial and Appeal Board (PTAB) rejected Thorne Research's attempt to invalidate the 807 patent. ChromaDex (CDXC) said it holds an exclusive license to the 807 patent for compositions including nicotinamide riboside (NR) from the Trustees of Dartmouth College. The decision, if upheld upon appeal, precludes Thorne from raising arguments before the PTAB in the New York District Court lawsuit brought by ChromaDex alleging that Thorne infringed the 807 patent, the company said in an Aug. 15 press release.

Shareholder Returns

CDXCUS Life SciencesUS Market
7D-10.6%1.9%3.2%
1Y-80.2%-19.8%-10.2%

Return vs Industry: CDXC underperformed the US Life Sciences industry which returned -19.8% over the past year.

Return vs Market: CDXC underperformed the US Market which returned -10.2% over the past year.

Price Volatility

Is CDXC's price volatile compared to industry and market?
CDXC volatility
CDXC Average Weekly Movement14.6%
Life Sciences Industry Average Movement11.0%
Market Average Movement7.7%
10% most volatile stocks in US Market16.9%
10% least volatile stocks in US Market3.2%

Stable Share Price: CDXC is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 15% a week.

Volatility Over Time: CDXC's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
n/a115Rob Friedhttps://www.chromadex.com

ChromaDex Corporation operates as a bioscience company focusing on healthy aging. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches on nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers, as well as to distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products.

ChromaDex Corporation Fundamentals Summary

How do ChromaDex's earnings and revenue compare to its market cap?
CDXC fundamental statistics
Market CapUS$115.81m
Earnings (TTM)-US$28.32m
Revenue (TTM)US$69.06m

1.7x

P/S Ratio

-4.1x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
CDXC income statement (TTM)
RevenueUS$69.06m
Cost of RevenueUS$27.04m
Gross ProfitUS$42.02m
Other ExpensesUS$70.34m
Earnings-US$28.32m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-0.41
Gross Margin60.85%
Net Profit Margin-41.01%
Debt/Equity Ratio0%

How did CDXC perform over the long term?

See historical performance and comparison